Codexis Inc. (NASDAQ:CDXS)’s share price traded up 1.4% during mid-day trading on Wednesday . The company traded as high as $4.38 and last traded at $4.27, with a volume of 76,637 shares. The stock had previously closed at $4.21.

A number of equities analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Codexis from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. HC Wainwright started coverage on shares of Codexis in a research note on Wednesday, June 1st. They issued a “buy” rating and a $6.00 price target for the company.

The firm’s market cap is $175.43 million. The firm has a 50 day moving average price of $4.20 and a 200 day moving average price of $3.82.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings data on Tuesday, August 9th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.09. The business earned $16 million during the quarter, compared to analysts’ expectations of $15.10 million. The business’s quarterly revenue was up 166.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.14) earnings per share. On average, equities analysts expect that Codexis Inc. will post ($0.20) EPS for the current year.

In related news, major shareholder Vivo Ventures Vii, Llc sold 50,000 shares of Codexis stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $4.27, for a total transaction of $213,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ventures Fund Vii L.P. Vivo sold 86,894 shares of Codexis stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $4.25, for a total transaction of $369,299.50. The disclosure for this sale can be found here.

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.